NKGN

NKGen Biotech, Inc. Common Stock

NKGN, USA

NKGen Biotech, Inc., a clinical-stage biotechnology company, develops and commercializes cell therapies for neurodegenerative and oncological diseases based on activated natural killer (NK) cells in the United States. The company develops SNK01, an autologous NK cell therapy candidate in Phase I/IIa trial for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's disease; and SNK02, which consists of an allogenic NK cell therapy that has completed Phase 1 trial and a HER2-CAR NK cell therapy candidate in pre-clinical trial to treat refractory solid tumors. It has a strategic partnership with HekaBio K.K., a Japan-based healthcare platform, to develop, conduct clinical trials, obtain regulatory approvals, manufacture, and commercialize the company's autologous NK cell therapy product candidates for central nervous system and autoimmune conditions in Japan. The company also has a license agreement with NKMAX Co., Ltd. for the research and development of its NK cell program. NKGen Biotech, Inc. was founded in 2017 and is headquartered in Santa Ana, California.

https://nkgenbiotech.com

Stock Price

$0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
NKGN
stock
NKGN

NKGen Biotech Secures New Promissory Note Financing TipRanks

Read more →
NKGN
stock
NKGN

Financial Review: Alpha Cognition (OTC:ACOGF) vs. NKGen Biotech (NYSE:NKGN) Defense World

Read more →

Showing 2 of 10

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Return on Assets (ROA)

-

Very Low

-122,558.33 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-1,069.02 %

Low ≤ 5%

High ≥ 15%

Investors

* Institutions hold a combined 0.00% of the total shares of NKGen Biotech, Inc. Common Stock

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2024-12-31

EPS Actual

0.15

EPS Estimate

0

EPS Difference

0.15

Surprise Percent

0%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(0.5)
Defensive
Cyclical / Risky(3)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
No Clear Moat(2.3)
GARP
Not Attractive for GARP(0)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2.5)
Net Net
Not Undervalued (Net-Net)(0)
Quality
Low Quality Business(0.5)
Value
Overpriced(0.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.